Correct Answer: D. Bcl-2
Bcl-2 (B-cell lymphoma-2) is the prototypical anti-apoptotic protein that prevents programmed cell death by blocking mitochondrial outer membrane permeabilization (MOMP). It was first identified in B-cell lymphomas where chromosomal translocation t(14;18) leads to Bcl-2 overexpression, preventing normal apoptosis of malignant cells. Bcl-2 works by sequestering pro-apoptotic proteins (BAX, BAK) and inhibiting cytochrome c release from mitochondria, thereby blocking the intrinsic apoptotic pathway. In the mitochondrial pathway, Bcl-2 family proteins act as gatekeepers—anti-apoptotic members (Bcl-2, Bcl-xL, Mcl-1) oppose pro-apoptotic members (BAX, BAK, BIM). This balance determines cell fate. Overexpression of Bcl-2 is seen in various Indian malignancies including lymphomas and some carcinomas, making it a critical oncogene. The Bcl-2/BAX ratio is a key determinant of apoptotic susceptibility in cancer cells, and this principle is exploited therapeutically by drugs like venetoclax (a Bcl-2 inhibitor used in CLL). Understanding Bcl-2 function is essential for comprehending both normal cell homeostasis and cancer biology.
Why the other options are wrong
A. P-53 — P-53 is a pro-apoptotic tumor suppressor, not anti-apoptotic. It activates apoptosis by transactivating pro-apoptotic genes (BAX, PUMA, NOXA) and repressing anti-apoptotic genes. P-53 is called the 'guardian of the genome' because it triggers apoptosis in response to DNA damage. Loss of P-53 (not overexpression) promotes cancer by preventing apoptosis of damaged cells. This is a common NBE trap—confusing tumor suppressors with oncogenes. B. BAK — BAK is a pro-apoptotic protein of the Bcl-2 family, not anti-apoptotic. It is a BAX-like effector that promotes mitochondrial outer membrane permeabilization and cytochrome c release, leading to caspase activation and apoptosis. BAK and BAX are functionally redundant executioners of the intrinsic apoptotic pathway. Overexpression of BAK would increase apoptosis, opposite to the question's requirement. C. K-ras — K-ras is an oncogenic GTPase involved in growth signaling (MAPK pathway), not directly in apoptosis regulation. While mutant K-ras promotes cell proliferation and can suppress apoptosis indirectly through survival signals, it is not classified as an anti-apoptotic factor in the canonical Bcl-2 family framework. K-ras mutations are common in Indian pancreatic and colorectal cancers but do not directly inhibit apoptosis like Bcl-2 does.
High-Yield Facts
- Bcl-2 is the prototypical anti-apoptotic protein that prevents cytochrome c release and blocks the intrinsic apoptotic pathway.
- t(14;18) translocation in B-cell lymphomas juxtaposes Bcl-2 to the immunoglobulin heavy chain promoter, causing Bcl-2 overexpression and lymphomagenesis.
- Bcl-2/BAX ratio determines apoptotic susceptibility; high Bcl-2:BAX favors survival, low ratio favors apoptosis.
- P-53 is pro-apoptotic (activates BAX, PUMA, NOXA); BAK is pro-apoptotic (executes MOMP); only Bcl-2 is anti-apoptotic.
- Venetoclax, a Bcl-2 inhibitor, is used in CLL and AML by blocking Bcl-2's anti-apoptotic function, forcing cancer cells into apoptosis.
Mnemonics
BAD vs. GOOD (Bcl-2 family mnemonic) BAD = BAX, BAK, BIM, BID, PUMA, NOXA (pro-apoptotic). GOOD = Bcl-2, Bcl-xL, Mcl-1 (anti-apoptotic). When BAD wins, cell dies. When GOOD wins, cell survives. Use this to instantly classify any Bcl-2 family member. Anti-apoptotic = Anti-death = Bcl-2 Only Bcl-2 (and its homologs Bcl-xL, Mcl-1) block apoptosis. All others in this question either promote apoptosis (P-53, BAK) or are unrelated (K-ras). Bcl-2 = survival signal.
NBE Trap
NBE pairs Bcl-2 with lymphomas to test if students know that Bcl-2 prevents apoptosis (making it oncogenic), not that it causes cancer directly. Students may confuse P-53 (tumor suppressor) with Bcl-2 (oncogene) if they forget that P-53 activates apoptosis in response to DNA damage.
Clinical Pearl
In Indian lymphoma patients, Bcl-2 overexpression (detected by immunohistochemistry or flow cytometry) is a marker of poor prognosis because these cells evade apoptosis. Venetoclax, now available in India, directly targets Bcl-2 and has revolutionized CLL treatment by forcing apoptosis in these resistant cells.
_Reference: Robbins Ch. 1 (Cell Injury & Death); Harrison Ch. 69 (Apoptosis & Necrosis)_